FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2408523293> ?p ?o ?g. }

• W2408523293 endingPage "13" @default.
• W2408523293 startingPage "9" @default.
• W2408523293 abstract "In-transit metastases develop in 5 to 8% of melanoma patients. They present as single or multiple (sub)cutaneous nodules close by the tumor (satellitosis <3 cm of the primary tumor; stage II) or scattered over the whole extremity (>3 cm from the primary tumor; stage IIIA). They can appear synchronously together with the primary tumor or as a regional relapse and precede most often the appearance of systemic metastases. The management of regionally recurrent melanoma remains a challenge at present. Various locoregional treatments are reviewed. The choice depends primarily on the number and size of the lesions and on the general condition of the patient. Treatments vary from (multiple) excision(s), laser-evaporation, intralesional injection of interferons, regional chemotherapy, e.g. intraarterial chemotherapy, isolated limb infusions and isolated limb perfusions. A single or only a few in-transit metastases are initially usually treated by surgical excision. Carbon dioxide laser management of recurrences has been reported successful only in the management of small nodules (<1.5 cm). Intralesional injections with interferons (α/β) yields modest response rates of short duration. Intraarterial chemotherapy is ineffective. Isolated limb infusions with application of a tourniquet seems more effective, but experience is very limited. Isolated Limb Perfusion (ILP) using an extracorporeal perfusion circuit is the most effective therapy available for inoperable melanoma, providing excellent local control but no clear survival benefit. However, about 25% of the patients with stage II to IIIA are alive after 5 to 10 years. Thus ILP can be curative. An overall response rate of about 80% (40% CR, 40% PR) can be obtained by a single perfusion with melphalan, the standard drug in this disease. Hyperthermia may improve response rates, but at the cost of increased regional toxicity. Perfusion with the combination of Tumor Necrosis Factor α (TNFα), Interferon-gamma (IFNγ) and melphalan has proven most effective, yielding a 80 to 90% complete response rate, and an overall response rate of 100%. Multiple lesions or rerecurrences in stage II to IIIA/AB are best treated by ILP, in particular ILP with melphalan +TNFα, resulting in 100% response rate. This last treatment is now available in a few perfusion centers in Europe. Reports often do not mention duration of local tumor control after ILP, in spite of the fact that this is the most important measurestick of success. The main issue for the future will be prolongation of the limb recurrence-free interval." @default.
• W2408523293 created "2016-06-24" @default.
• W2408523293 creator A5049419102 @default.
• W2408523293 creator A5052579165 @default.
• W2408523293 date "1996-02-01" @default.
• W2408523293 modified "2023-10-16" @default.
• W2408523293 title "Treatment of melanoma in-transit metastases confined to the limb" @default.
• W2408523293 cites W1868723016 @default.
• W2408523293 cites W1889451488 @default.
• W2408523293 cites W1916563986 @default.
• W2408523293 cites W1962681190 @default.
• W2408523293 cites W1964131973 @default.
• W2408523293 cites W1967535494 @default.
• W2408523293 cites W1971622976 @default.
• W2408523293 cites W1974292298 @default.
• W2408523293 cites W1975630956 @default.
• W2408523293 cites W1976261819 @default.
• W2408523293 cites W1978668737 @default.
• W2408523293 cites W1984698255 @default.
• W2408523293 cites W2000998098 @default.
• W2408523293 cites W2002370461 @default.
• W2408523293 cites W2002819116 @default.
• W2408523293 cites W2007984865 @default.
• W2408523293 cites W2020646217 @default.
• W2408523293 cites W2033005592 @default.
• W2408523293 cites W2033479047 @default.
• W2408523293 cites W2046411660 @default.
• W2408523293 cites W2053924995 @default.
• W2408523293 cites W2057123987 @default.
• W2408523293 cites W2061688172 @default.
• W2408523293 cites W2065807715 @default.
• W2408523293 cites W2068542879 @default.
• W2408523293 cites W2073277368 @default.
• W2408523293 cites W2073482429 @default.
• W2408523293 cites W2076970414 @default.
• W2408523293 cites W2087359455 @default.
• W2408523293 cites W2223024204 @default.
• W2408523293 cites W2416836988 @default.
• W2408523293 doi "https://doi.org/10.1007/bf02625948" @default.
• W2408523293 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8783582" @default.
• W2408523293 hasPublicationYear "1996" @default.
• W2408523293 type Work @default.
• W2408523293 sameAs 2408523293 @default.
• W2408523293 citedByCount "19" @default.
• W2408523293 countsByYear W24085232932018 @default.
• W2408523293 countsByYear W24085232932019 @default.
• W2408523293 crossrefType "journal-article" @default.
• W2408523293 hasAuthorship W2408523293A5049419102 @default.
• W2408523293 hasAuthorship W2408523293A5052579165 @default.
• W2408523293 hasConcept C121608353 @default.
• W2408523293 hasConcept C126322002 @default.
• W2408523293 hasConcept C126838900 @default.
• W2408523293 hasConcept C141071460 @default.
• W2408523293 hasConcept C146357865 @default.
• W2408523293 hasConcept C146957229 @default.
• W2408523293 hasConcept C151730666 @default.
• W2408523293 hasConcept C2776694085 @default.
• W2408523293 hasConcept C2777658100 @default.
• W2408523293 hasConcept C2778684742 @default.
• W2408523293 hasConcept C2779013556 @default.
• W2408523293 hasConcept C2780283643 @default.
• W2408523293 hasConcept C502942594 @default.
• W2408523293 hasConcept C71924100 @default.
• W2408523293 hasConcept C86803240 @default.
• W2408523293 hasConceptScore W2408523293C121608353 @default.
• W2408523293 hasConceptScore W2408523293C126322002 @default.
• W2408523293 hasConceptScore W2408523293C126838900 @default.
• W2408523293 hasConceptScore W2408523293C141071460 @default.
• W2408523293 hasConceptScore W2408523293C146357865 @default.
• W2408523293 hasConceptScore W2408523293C146957229 @default.
• W2408523293 hasConceptScore W2408523293C151730666 @default.
• W2408523293 hasConceptScore W2408523293C2776694085 @default.
• W2408523293 hasConceptScore W2408523293C2777658100 @default.
• W2408523293 hasConceptScore W2408523293C2778684742 @default.
• W2408523293 hasConceptScore W2408523293C2779013556 @default.
• W2408523293 hasConceptScore W2408523293C2780283643 @default.
• W2408523293 hasConceptScore W2408523293C502942594 @default.
• W2408523293 hasConceptScore W2408523293C71924100 @default.
• W2408523293 hasConceptScore W2408523293C86803240 @default.
• W2408523293 hasIssue "1" @default.
• W2408523293 hasLocation W24085232931 @default.
• W2408523293 hasLocation W24085232932 @default.
• W2408523293 hasOpenAccess W2408523293 @default.
• W2408523293 hasPrimaryLocation W24085232931 @default.
• W2408523293 hasRelatedWork W1969505757 @default.
• W2408523293 hasRelatedWork W2002370461 @default.
• W2408523293 hasRelatedWork W2032717243 @default.
• W2408523293 hasRelatedWork W2086094746 @default.
• W2408523293 hasRelatedWork W2153814163 @default.
• W2408523293 hasRelatedWork W2399161820 @default.
• W2408523293 hasRelatedWork W2410278223 @default.
• W2408523293 hasRelatedWork W2416567523 @default.
• W2408523293 hasRelatedWork W2997632039 @default.
• W2408523293 hasRelatedWork W4366782918 @default.
• W2408523293 hasVolume "28" @default.
• W2408523293 isParatext "false" @default.
• W2408523293 isRetracted "false" @default.
• W2408523293 magId "2408523293" @default.

• next